| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051176999 |
| P356 | DOI | 10.1186/1478-7954-5-11 |
| P932 | PMC publication ID | 2213637 |
| P698 | PubMed publication ID | 17967185 |
| P5875 | ResearchGate publication ID | 5879353 |
| P50 | author | Sue Goldie | Q7634103 |
| Karen M Kuntz | Q87347413 | ||
| Jeremy Goldhaber-Fiebert | Q65967291 | ||
| Joshua A Salomon | Q37607615 | ||
| P2093 | author name string | Jesse Ortendahl | |
| Natasha K Stout | |||
| P2860 | cites work | Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses | Q21144710 |
| Estimating age conditional probability of developing disease from surveillance data | Q24792037 | ||
| The epidemiological impact of antiretroviral use predicted by mathematical models: a review. | Q24814633 | ||
| Prevalence of HPV infection among females in the United States | Q28290509 | ||
| Approximate Is Better than "Exact" for Interval Estimation of Binomial Proportions | Q29041279 | ||
| Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada | Q31030012 | ||
| Concordance of human papillomavirus in the cervix and urine among inner city adolescents | Q33180951 | ||
| Novel metaheuristic for parameter estimation in nonlinear dynamic biological systems | Q33262500 | ||
| Cost-effectiveness of a potential vaccine for human papillomavirus | Q33865463 | ||
| Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group | Q33954679 | ||
| Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions. | Q33954692 | ||
| Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis | Q33975138 | ||
| Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral | Q34153160 | ||
| Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group | Q34313864 | ||
| Effect of screening and adjuvant therapy on mortality from breast cancer | Q34463105 | ||
| Evaluation of cervical cytology | Q34582965 | ||
| Age-conditional probabilities of developing cancer | Q34667627 | ||
| The frequency of Pap smear screening in the United States | Q34731765 | ||
| Empirically calibrated model of hepatitis C virus infection in the United States | Q34948964 | ||
| A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine | Q35199478 | ||
| Evaluating human papillomavirus vaccination programs | Q35895952 | ||
| Geographic disparities in cervical cancer mortality: what are the roles of risk factor prevalence, screening, and use of recommended treatment? | Q36109751 | ||
| Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results | Q81024849 | ||
| The prevalence of HR-HPV DNA in ASC-US Pap smears: A military population study | Q81484693 | ||
| HPV 16 and cigarette smoking as risk factors for high-grade cervical intra-epithelial neoplasia. | Q50863212 | ||
| Natural history of cervicovaginal papillomavirus infection in young women. | Q50909200 | ||
| Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. | Q51005488 | ||
| Increasing the efficiency of Monte Carlo cohort simulations with variance reduction techniques. | Q51129446 | ||
| Model uncertainty--parameter uncertainty versus conceptual models. | Q51316077 | ||
| Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. | Q51931359 | ||
| The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. | Q51968734 | ||
| A longitudinal analysis of human papillomavirus 16 infection, nutritional status, and cervical dysplasia progression | Q52340036 | ||
| Is human papillomavirus testing an effective triage method for detection of high-grade (grade 2 or 3) cervical intraepithelial neoplasia? | Q53716139 | ||
| Persistent area socioeconomic disparities in U.S. incidence of cervical cancer, mortality, stage, and survival, 1975–2000 | Q56091935 | ||
| Multiparameter Calibration of a Natural History Model of Cervical Cancer | Q57089398 | ||
| Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine | Q57089428 | ||
| Epidemiology of Acquisition and Clearance of Cervical Human Papillomavirus Infection in Women from a High‐Risk Area for Cervical Cancer | Q57089472 | ||
| Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System | Q57278988 | ||
| Overview of the European and North American studies on HPV testing in primary cervical cancer screening | Q57414808 | ||
| Monte Carlo probabilistic sensitivity analysis for patient level simulation models: efficient estimation of mean and variance using ANOVA | Q59297509 | ||
| Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia | Q60197523 | ||
| Prevalence and persistence of human papillomavirus in postmenopausal age women | Q60654488 | ||
| Cost-Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies | Q61881629 | ||
| Cervical cancer screening among low-income women: results of a national screening program, 1991-1995 | Q64132602 | ||
| Cervical screening in the National Breast and Cervical Cancer Early Detection Program, 1995-2001 | Q64133808 | ||
| Dysplasia and carcinoma in situ of the uterine cervix: prevalence in very young women (under age 22). A one-year study in a health plan population | Q67441883 | ||
| Prevalence of dysplasia and cancer of the cervix in a nationwide, planned parenthood population | Q68343780 | ||
| Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities | Q71743047 | ||
| PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears | Q71937687 | ||
| The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months | Q72190175 | ||
| Persistence of type-specific human papillomavirus infection among cytologically normal women | Q72238714 | ||
| Human papillomavirus and prognosis of invasive cervical cancer: a population-based study | Q73703032 | ||
| High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy | Q73824709 | ||
| Determinants of genital human papillomavirus detection in a US population | Q73851528 | ||
| Pap test results among low-income youth: prevalence of dysplasia and practice implications | Q74186426 | ||
| Uterine cervical dysplasia and cancer: identification of c-myc status by quantitative polymerase chain reaction | Q77338022 | ||
| Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions | Q77845976 | ||
| Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study | Q78001750 | ||
| Distribution of human papillomavirus types in cervicovaginal washings from women evaluated in a sexually transmitted diseases clinic | Q78614346 | ||
| The Wisconsin Breast Cancer Epidemiology Simulation Model | Q79220380 | ||
| Impact of adjuvant therapy and mammography on U.S. mortality from 1975 to 2000: comparison of mortality results from the cisnet breast cancer base case analysis | Q79220390 | ||
| The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women. | Q50638852 | ||
| Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. | Q50723929 | ||
| Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. | Q50741157 | ||
| Diagnoses and outcomes in cervical cancer screening: a population-based study. | Q50747235 | ||
| Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. | Q50789678 | ||
| Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer | Q36128026 | ||
| Evidence synthesis, parameter correlation and probabilistic sensitivity analysis | Q36359124 | ||
| Bayesian methods for evidence synthesis in cost-effectiveness analysis | Q36381197 | ||
| Determinants of genital human papillomavirus infection in young women | Q36403114 | ||
| Model building on the basis of Dutch cervical cancer screening data | Q36497153 | ||
| Chapter 2: The burden of HPV-related cancers | Q36584354 | ||
| Chapter 13: Current findings from prophylactic HPV vaccine trials | Q36584357 | ||
| Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling | Q36584372 | ||
| Chapter 7: Achievements and limitations of cervical cytology screening | Q36584424 | ||
| Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland | Q36609838 | ||
| Prevalence of cervical intraepithelial neoplasia in sexually active teenagers and young adults. Results of data analysis of mass Papanicolaou screening of 796,337 women in the United States in 1981. | Q36624153 | ||
| Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies | Q36644814 | ||
| Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis | Q36647828 | ||
| Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis | Q36670753 | ||
| The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm. | Q36715975 | ||
| Detection of genital human papillomavirus and associated cytological abnormalities among college women | Q36896687 | ||
| A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women | Q36980796 | ||
| Model for assessing human papillomavirus vaccination strategies | Q37302509 | ||
| Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix | Q37870300 | ||
| Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control | Q37873130 | ||
| A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection | Q37892308 | ||
| Comparison of human papillomavirus genotypes in archival cervical cancer specimens from Alaska natives, Greenland natives and Danish Caucasians | Q38465451 | ||
| Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma | Q38474163 | ||
| Detection and typing of human papillomavirus in archival cervical cancer specimens by DNA amplification with consensus primers | Q38489934 | ||
| Prevalence of human papillomavirus genotypes in women from three clinical settings | Q38940141 | ||
| Increased prevalence of abnormal Papanicolaou smears in urban adolescents | Q39445802 | ||
| Incidence of cervical squamous intraepithelial lesions in HIV-infected women | Q39530213 | ||
| ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants | Q39548781 | ||
| Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial | Q39558136 | ||
| Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population | Q39672720 | ||
| Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty | Q40245291 | ||
| Gaussian process modeling in conjunction with individual patient simulation modeling: a case study describing the calculation of cost-effectiveness ratios for the treatment of established osteoporosis | Q40526696 | ||
| Cost-effectiveness of breast cancer screening: preliminary results of a systematic review of the literature | Q40832759 | ||
| Natural history of cervical intraepithelial neoplasia: a critical review. | Q40891994 | ||
| Genital HPV infections in children and adolescents. | Q40929128 | ||
| Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer | Q41127637 | ||
| Prevalence of and risks for cervical human papillomavirus infection and squamous intraepithelial lesions in adolescent girls: impact of infection with human immunodeficiency virus | Q41718422 | ||
| Prognostic significance of polymerase chain reaction detected human papillomavirus of tumors and lymph nodes in surgically treated stage IB cervical cancer | Q41955314 | ||
| Biotinyl-tyramide-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia | Q42528670 | ||
| Prevalence of infection with carcinogenic human papillomavirus among older women | Q42783840 | ||
| Racial differences in the risk of invasive squamous-cell cervical cancer | Q43587167 | ||
| The natural history of type-specific human papillomavirus infections in female university students. | Q43919306 | ||
| Costs and benefits of different strategies to screen for cervical cancer in less-developed countries | Q44164630 | ||
| Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs | Q44388059 | ||
| Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests | Q44529186 | ||
| Benefits and costs of using HPV testing to screen for cervical cancer | Q44743125 | ||
| Cost-effectiveness analysis of liquid-based cytology and human papillomavirus testing in cervical cancer screening | Q45092160 | ||
| Relative and attributable risk for cervical cancer: a comparative study in the United States and Italy | Q45239973 | ||
| Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance | Q45305963 | ||
| The theoretical population-level impact of a prophylactic human papilloma virus vaccine | Q45730281 | ||
| Human papillomavirus infection in women infected with the human immunodeficiency virus | Q45759660 | ||
| Determinants of genital human papillomavirus infection in low-income women in Washington, D.C. | Q46270399 | ||
| Natural history of cervical squamous intraepithelial lesions: a meta-analysis | Q46341755 | ||
| Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy | Q46365761 | ||
| Mutations of p53 and human papillomavirus infection in cervical carcinoma | Q46621463 | ||
| Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. | Q46635970 | ||
| Cost-effectiveness of cervical-cancer screening in five developing countries | Q46807926 | ||
| Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia | Q47650204 | ||
| Contraceptive and reproductive risk factors for cervical intraepithelial neoplasia in American Indian women | Q47652302 | ||
| Telomerase and human papillomavirus as diagnostic adjuncts for cervical dysplasia and carcinoma | Q47677137 | ||
| A case-control study of risk factors for invasive cervical cancer among U.S. women exposed to oncogenic types of human papillomavirus. | Q48520131 | ||
| Prevalence and incidence rates of cervical atypia. A computerized file analysis of 148,735 patients | Q48670985 | ||
| Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy | Q50129780 | ||
| Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong | Q50144393 | ||
| Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey | Q50145813 | ||
| Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. | Q50179156 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| United States of America | Q30 | ||
| P304 | page(s) | 11 | |
| P577 | publication date | 2007-10-29 | |
| P1433 | published in | Population Health Metrics | Q15765016 |
| P1476 | title | Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination | |
| P478 | volume | 5 |
| Q34083083 | An updated natural history model of cervical cancer: derivation of model parameters |
| Q36971738 | Anal cancer and human papillomaviruses in heterosexual men. |
| Q40025709 | Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications |
| Q39553763 | Calibrating models in economic evaluation: a seven-step approach. |
| Q28749665 | Calibration methods used in cancer simulation models and suggested reporting guidelines |
| Q39553755 | Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country |
| Q39825094 | Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States |
| Q37087365 | Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches |
| Q51148505 | Cost-effectiveness of 12- and 15-year-old girls' human papillomavirus 16/18 population-based vaccination programmes in Lithuania. |
| Q34461262 | Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary. |
| Q38850707 | Cost-effectiveness of an HPV self-collection campaign in Uganda: comparing models for delivery of cervical cancer screening in a low-income setting |
| Q33909353 | Cost-effectiveness of cervical cancer screening and preventative cryotherapy at an HIV treatment clinic in Kenya |
| Q34997604 | Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination |
| Q35927132 | Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway |
| Q45049771 | Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in Thailand |
| Q37425356 | Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States |
| Q93030550 | Development of an Empirically Calibrated Model of Esophageal Squamous Cell Carcinoma in High-Risk Regions |
| Q39553769 | Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. |
| Q34605012 | Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review |
| Q34199773 | Efficacy of vaccination against HPV infections to prevent cervical cancer in France: present assessment and pathways to improve vaccination policies |
| Q45074054 | Estimating the value of point-of-care HPV testing in three low- and middle-income countries: a modeling study. |
| Q33724701 | Estimation of the cost-effectiveness of HIV prevention portfolios for people who inject drugs in the United States: A model-based analysis |
| Q35889801 | Evolution of cervical cancer screening and prevention in United States and Canada: implications for public health practitioners and clinicians |
| Q38549643 | Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies |
| Q37315939 | HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women |
| Q36785915 | Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India |
| Q58696169 | How various design decisions on matching individuals in relationships affect the outcomes of microsimulations of sexually transmitted infection epidemics |
| Q46659871 | Incorporating calibrated model parameters into sensitivity analyses: deterministic and probabilistic approaches |
| Q51434170 | Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. |
| Q53290879 | Is human papillomavirus screening preferable to current policies in vaccinated and unvaccinated women? A cost-effectiveness analysis. |
| Q63446595 | Is it Time for Reporting Guidelines for Calibration Methods? |
| Q45369064 | Mathematical models of cervical cancer prevention in Latin America and the Caribbean |
| Q33378841 | Mathematical models of cervical cancer prevention in the Asia Pacific region |
| Q35223397 | Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities |
| Q33969384 | Modeling and calibration for exposure to time-varying, modifiable risk factors: the example of smoking behavior in India |
| Q37291448 | Modeling cervical cancer prevention in developed countries |
| Q35906207 | Quantifying demographic and socioeconomic transitions for computational epidemiology: an open-source modeling approach applied to India |
| Q42589331 | Re: Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination |
| Q93549505 | Response |
| Q41350473 | Some Health States Are Better Than Others: Using Health State Rank Order to Improve Probabilistic Analyses |
| Q37526808 | Techniques and predictive models to improve prostate cancer detection |
| Q26851181 | The Possible Effects on Socio-Economic Inequalities of Introducing HPV Testing as Primary Test in Cervical Cancer Screening Programs |
| Q41499207 | The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador |
| Q37993109 | The cost effectiveness of human papillomavirus vaccines: a systematic review |
| Q38851920 | To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings. |
| Q35127307 | Too late to vaccinate? The incremental benefits and cost-effectiveness of a delayed catch-up program using the 4-valent human papillomavirus vaccine in Norway |
| Q37352821 | Trade-offs in cervical cancer prevention: balancing benefits and risks |
| Q30712681 | Type-specific prevalence of high-risk human papillomavirus by cervical cytology and age: Data from the health check-ups of 7,014 Korean women |
| Q46001455 | Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. |
| Q54962711 | When and how often to screen for cervical cancer in three low- and middle-income countries: A cost-effectiveness analysis. |
Search more.